Program
tislelizumab
Also written as “Tislelizumab”, “BGB-A317” and “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Esophageal Squamous Cell Carcinoma · Carcinoma, Hepatocellular · Stomach Neoplasms · Hodgkin Disease, led by 21 companies.
Drug pageTislelizumab: every studyMany companies study it; this page follows only the 74 they lead. All 434 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicinesits history only | 539 open or running | phase 3since Nov 27, 2017 | Mar 26, 2015 | Nov 2026phase 2 · NCT03736889 |
| RemeGenits history only | 22 open or running | phase 3since Apr 17, 2025 | Apr 17, 2025 | May 15, 2028phase 3 · NCT06944496 |
| Antengeneits history only | 10 open or running | phase 2since May 25, 2020 | May 25, 2020 | none ahead |
| Beijing Aosaikang Pharmaceuticalits history only | 11 open or running | phase 2since Nov 21, 2022 | Nov 21, 2022 | none ahead |
| Beijing Biostar Pharmaceuticalsits history only | 11 open or running | phase 2since Sep 18, 2026 | Sep 18, 2026 | Sep 20, 2028phase 2 · NCT07842276 |
| BriaCell Therapeuticsits history only | 11 open or running | phase 2since Jun 11, 2024 | Jun 11, 2024 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | phase 3since Nov 9, 2018 | Nov 9, 2018 | none ahead |
| Changchun GeneScience Pharmaceuticalits history only | 10 open or running | phase 1since Jun 16, 2022 | Jun 16, 2022 | none ahead |
| HUTCHMEDits history only | 10 open or running | phase 2since Sep 23, 2020 | Sep 23, 2020 | none ahead |
| Immix Biopharmaits history only | 11 open or running | phase 2since Jan 4, 2023 | Jan 4, 2023 | none ahead |
| Immune-Onc Therapeuticsits history only | 10 open or running | phase 1since Aug 12, 2022 | Aug 12, 2022 | none ahead |
| Jazz Pharmaceuticalsits history only | 11 open or running | phase 3since Nov 5, 2021 | Nov 5, 2021 | none ahead |
| Jiangsu Healthy Life Innovation Medical Technologyits history only | 11 open or running | phase 2since Mar 19, 2024 | Mar 19, 2024 | none ahead |
| Jiangsu Yahong Meditech Co., Ltd aka Asierisits history only | 10 open or running | phase 2since Mar 21, 2021 | Mar 21, 2021 | none ahead |
| Leap Therapeuticsits history only | 10 open or running | phase 2since Apr 23, 2020 | Apr 23, 2020 | none ahead |
| Nanjing Leads Biolabsits history only | 10 open or running | phase 2since Aug 22, 2022 | Aug 22, 2022 | none ahead |
| Novartisits history only | 10 open or running | phase 3since Mar 17, 2023 | Mar 17, 2023 | none ahead |
| Shanghai Gopherwood Biotechits history only | 10 open or running | phase 2since Aug 15, 2022 | Aug 15, 2022 | none ahead |
| Shanghai Kanda Biotechnologyits history only | 11 open or running | phase 2since May 24, 2023 | May 24, 2023 | none ahead |
| Sino Biopharmaceuticalits history only | 11 open or running | phase 2since Feb 9, 2025 | Feb 9, 2025 | none ahead |
| Suzhou Zelgen Biopharmaceuticalsits history only | 11 open or running | phase 2since Jul 25, 2025 | Jul 25, 2025 | Dec 2027phase 2 · NCT07099547 |
Also a collaborator on its studies: Myriad Genetic Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 46 earlier studies, Oct 17, 2018 to Jan 4, 2023.
- Jun 9, 2017Named tislelizumabINNProposed as its International Nonproprietary Name in WHO's List 117
- Mar 17, 2023Novartis’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to NovartisNovartis · NCT05791097
- May 24, 2023Shanghai Kanda Biotechnology’s first study: phase 2 study in Advanced HCCNew to Shanghai Kanda BiotechnologyShanghai Kanda Biotechnology · NCT05906524 · 85 planned · China
- Jul 31, 2023Phase 1 study in Advanced Solid TumorBeOne Medicines · NCT05981703 · 337 planned · United States, Australia, China and more
- Oct 16, 2023Phase 1 study in Carcinoma, Non-Small-Cell LungBeOne Medicines · NCT06091943 · 62 enrolled · China, Georgia, Moldova
- Mar 19, 2024Jiangsu Healthy Life Innovation Medical Technology’s first study: phase 2 study in GlioblastomaNew to Jiangsu Healthy Life Innovation Medical TechnologyJiangsu Healthy Life Innovation Medical Technology · NCT06353360 · 30 planned · China
- Jun 11, 2024BriaCell Therapeutics’ first study: phase 2 study in Breast NeoplasmsNew to BriaCell TherapeuticsBriaCell Therapeutics · NCT06471673 · 18 planned · United States
- Feb 9, 2025Sino Biopharmaceutical’s first study: phase 2 study in Advanced Solid TumorNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06825494 · 194 planned · China
- Apr 17, 2025RemeGen’s first study: phase 3 study in Stomach NeoplasmsNew to RemeGenRemeGen · NCT06944496 · 616 planned · China
- Jun 20, 2025Phase 3 study in Metastatic Gastric AdenocarcinomaBeOne Medicines · NCT07043400 · 351 planned · United States, Argentina, Austria and more
- Jul 25, 2025Suzhou Zelgen Biopharmaceuticals’ first study: phase 2 study in Biliary Tract CarcinomaNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT07099547 · 60 planned · China
- Apr 21, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07554521 · 30 planned · United States
- Jul 22, 2026Phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07733180 · 30 planned · Japan
- Sep 18, 2026Beijing Biostar Pharmaceuticals’ first study: phase 2 study in SarcomaNew to Beijing Biostar PharmaceuticalsBeijing Biostar Pharmaceuticals · NCT07842276 · 49 planned · China
- Nov 1, 2026Phase 3 study in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRemeGen · NCT07935369 · 680 planned · China
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Transitional CellBeOne Medicines · NCT03967977
- Oct 30, 2027Primary completion: phase 3 study in Metastatic Gastric AdenocarcinomaBeOne Medicines · NCT07043400
- Dec 2027Primary completion: phase 2 study in Biliary Tract CarcinomaSuzhou Zelgen Biopharmaceuticals · NCT07099547
- Feb 28, 2028Primary completion: phase 2 study in Esophageal Squamous Cell CarcinomaBeOne Medicines · NCT07733180
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The newest 60 of 74 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07935369Advanced Gastric or Gastroesophageal Junction Adenocarcinoma · China | 3 | Not yet recruiting | RemeGen | Apr 30, 2030 | 680 |
| NCT07842276Sarcoma · China | 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals | Sep 20, 2028 | 49 |
| NCT07733180Esophageal Squamous Cell Carcinoma · Japan | 2 | Recruiting | BeOne Medicines | Feb 28, 2028 | 30 |
| NCT07554521Esophageal Squamous Cell Carcinoma · United States | 2 | Recruiting | BeOne Medicines | Dec 31, 2031 | 30 |
| NCT07099547Biliary Tract Carcinoma · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Dec 2027 | 60 |
| NCT07043400Metastatic Gastric Adenocarcinoma · United States, Argentina, Austria and more | 3 | Recruiting | BeOne Medicines | Oct 30, 2027 | 351 |
| NCT06944496Stomach Neoplasms · China | 3 | Not yet recruiting | RemeGen | May 15, 2028 | 616 |
| NCT06825494Advanced Solid Tumor · China | 2 | Recruiting | Sino Biopharmaceutical | Mar 2026 | 194 |
| NCT06471673Breast Neoplasms · United States | 2 | Recruiting | BriaCell Therapeutics | Apr 30, 2025 | 18 |
| NCT06353360Glioblastoma · China | 2 | Recruiting | Jiangsu Healthy Life Innovation Medical Technology | Jul 15, 2025 | 30 |
| NCT06091943Carcinoma, Non-Small-Cell Lung · China, Georgia, Moldova | 1 | Completed | BeOne Medicines | Jul 31, 2025 | 62 |
| NCT05981703Advanced Solid Tumor · United States, Australia, China and more | 1 | Recruiting | BeOne Medicines | Feb 28, 2029 | 337 |
| NCT05906524Advanced HCC · China | 2 | Not yet recruiting | Shanghai Kanda Biotechnology | Apr 30, 2025 | 85 |
| NCT05791097Carcinoma, Non-Small-Cell Lung | 3 | Withdrawn | Novartis | Dec 24, 2027 | 0 |
| NCT05840835Advanced Solid Tumor · Brazil | 2 | Recruiting | Immix Biopharma | Jan 24, 2024 | 60 |
| NCT05661955Carcinoma, Transitional Cell · China | 2 | Active, not recruiting | BeOne Medicines | May 27, 2025 | 113 |
| NCT05644626Solid Tumors | 1 | Withdrawn | BeOne Medicines | Mar 2025 | 0 |
| NCT05635708Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 2 | Completed | BeOne Medicines | Dec 19, 2025 | 418 |
| NCT05632939Stomach Neoplasms · China | 2 | Active, not recruiting | Beijing Aosaikang Pharmaceutical | Oct 31, 2025 | 62 |
| NCT05609370Colorectal Neoplasms · United States, Australia, China and more | 2 | Active, not recruiting | BeOne Medicines | May 23, 2025 | 113 |
| NCT05577702Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | BeOne Medicines | Dec 13, 2024 | 121 |
| NCT05564338Carcinoma, Hepatocellular | 3 | Withdrawn | BeOne Medicines | Apr 30, 2027 | 0 |
| NCT05516914Neoplasms · China | 2 | Completed | Nanjing Leads Biolabs | Jan 30, 2026 | 98 |
| NCT05505877Parkinson Disease 4, Autosomal Dominant Lewy Body · China | 2 | UNKNOWN | Shanghai Gopherwood Biotech | Oct 31, 2024 | 160 |
| NCT05508100Advanced Solid Tumor · China | 1 | Completed | Immune-Onc Therapeutics | Apr 30, 2024 | 38 |
| NCT05494762Solid Tumor · United States, Australia | 1 | Terminated | BeOne Medicines | Feb 24, 2025 | 55 |
| NCT05461794Esophageal Squamous Cell Carcinoma · China | 2 | Terminated | BeOne Medicines | Feb 26, 2024 | 96 |
| NCT05441046Malignant Solid Tumors · China | 1 | UNKNOWN | Changchun GeneScience Pharmaceutical | Jun 2024 | 120 |
| NCT05267054Lymphoma, Large B-Cell, Diffuse · China | 2 | Completed | BeOne Medicines | Aug 30, 2024 | 53 |
| NCT05152147Stomach Neoplasms · Argentina, Australia, Belgium and more | 3 | Active, not recruiting | Jazz Pharmaceuticals | Jul 15, 2026 | 920 |
| NCT05116085Colorectal Neoplasms · China | 2 | Completed | BeOne Medicines | Sep 26, 2023 | 33 |
| NCT05014828Advanced Solid Tumor · China | 2 | Completed | BeOne Medicines | Oct 20, 2023 | 58 |
| NCT04974047Resectable Esophageal Squamous Cell Carcinoma · China | 2 | Completed | BeOne Medicines | Apr 17, 2023 | 70 |
| NCT04948697Advanced Hepatocellular Carcinoma · China, Taiwan | 2 | Completed | BeOne Medicines | Feb 1, 2024 | 94 |
| NCT04921358Carcinoma, Non-Small-Cell Lung · Australia, China | 3 | Terminated | BeOne Medicines | Dec 20, 2023 | 377 |
| NCT04813107Muscle Invasive Bladder Cancer · United States, China | 2 | UNKNOWN | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Nov 1, 2023 | 79 |
| NCT04746924Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Terminated | BeOne Medicines | May 30, 2025 | 669 |
| NCT04716634Advanced Solid Tumors · China, Korea, Republic of | 2 | Completed | BeOne Medicines | Feb 22, 2024 | 84 |
| NCT04693234Uterine Cervical Neoplasms · Bulgaria, China, Korea, Republic of and more | 2 | Completed | BeOne Medicines | Jun 16, 2022 | 178 |
| NCT04649385Advanced Solid Tumor · United States, Australia, China and more | 1 | Completed | BeOne Medicines | Oct 17, 2025 | 157 |
| NCT04866017Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more | 3 | Terminated | BeOne Medicines | Oct 17, 2023 | 63 |
| NCT04577963Triple Negative Breast Neoplasms · United States | 2 | Terminated | HUTCHMED | Jun 18, 2024 | 52 |
| NCT04486391Classical Hodgkin Lymphoma · China | 3 | Terminated | BeOne Medicines | Oct 13, 2025 | 3 |
| NCT04425070Lymphoma, T-Cell, Peripheral · China | 2 | Terminated | Antengene | Dec 30, 2025 | 56 |
| NCT04401800Carcinoma, Hepatocellular · China | 2 | Completed | BeOne Medicines | Dec 1, 2022 | 64 |
| NCT04379635Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | BeOne Medicines | Aug 21, 2023 | 453 |
| NCT04363801Stomach Neoplasms · United States, Germany, South Korea | 2 | Terminated | Leap Therapeutics | Mar 31, 2025 | 247 |
| NCT04318080Classical Hodgkin Lymphoma · United States, Australia | 2 | Completed | BeOne Medicines | Dec 12, 2022 | 46 |
| NCT04276493Breast Neoplasms · China, South Korea, Taiwan | 2 | Completed | BeOne Medicines | Dec 7, 2023 | 71 |
| NCT04164199Advanced Malignancies · United States, Australia, China and more | 3 | Completed | BeOne Medicines | May 23, 2026 | 404 |
| NCT04068519Advanced Solid Tumors · China | 2 | Completed | BeOne Medicines | Dec 1, 2018 | 300 |
| NCT04005716Small Cell Lung Carcinoma · China | 3 | Completed | BeOne Medicines | Apr 19, 2023 | 457 |
| NCT04004221Locally Advanced or Metastatic Urothelial Bladder Cancer · China, Korea, Republic of | 2 | Completed | BeOne Medicines | Sep 16, 2019 | 113 |
| NCT03967977Carcinoma, Transitional Cell · China, Taiwan | 3 | Active, not recruiting | BeOne Medicines | Jun 30, 2027 | 420 |
| NCT03957590Esophageal Squamous Cell Carcinoma · China | 3 | Completed | BeOne Medicines | Jan 8, 2025 | 370 |
| NCT03924986Recurrence · China, Taiwan, Thailand | 3 | Completed | BeOne Medicines | Mar 26, 2021 | 263 |
| NCT03783442Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Completed | BeOne Medicines | Feb 28, 2022 | 649 |
| NCT03777657Gastric, or Gastroesophageal Junction Adenocarcinoma · United States, China, France and more | 3 | Completed | BeOne Medicines | Feb 28, 2023 | 997 |
| NCT03745222Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 3 | Terminated | Bristol-Myers Squibb | Jun 26, 2019 | 1 |
| NCT03744468Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in · United States, Australia, France and more | 2 | Completed | BeOne Medicines | Feb 6, 2025 | 147 |
How it is read
Names in the registry
- “Tislelizumab”, 57 entries
- “BGB-A317”, 2 entries
- “Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)”, 1 entry
- “Tislelizumab (BGB-A317)”, 1 entry
- “Subcutaneous Tislelizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 13 studies
- Esophageal Squamous Cell Carcinoma, 7 studies
- Carcinoma, Hepatocellular, 5 studies
- Stomach Neoplasms, 4 studies
- Hodgkin Disease, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.